Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias

Wilson Wong, Harris N. Paviou, Ulrika M. Birgersdotter, Daniel E. Hillernan, Syed M. Mohiuddin, Dan M. Roden

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Sematilide, a close structural analog of N-acetylprocainamide, prolongs cardiac action potentials in vitro, whereas it does not depress maximum action potential upstroke slope, a "class III" action. This report outlines an evaluation of the clinical pharmacologic actions of sematilide in 14 patients with chronic high-frequency nonsustained ventricular arrhythmias. In all, 36 intravenous infusions (range 0.15 to 1.5 mg/kg over 15 minutes) were administered in a dose-ranging, placebo-controlled study design. Sematilide prolonged rate-corrected QT (QTc) in a dose- and concentration-related fashion, did not alter PR or QRS, and slowed heart rate at high concentrations (≥2 μg/ml). The relations between dose and total area under the time-concentration curve, dose and peak plasma concentration, and peak plasma concentration and increase in QTc were linear (r = 0.66 to 0.92; p

Original languageEnglish (US)
Pages (from-to)206-212
Number of pages7
JournalThe American Journal of Cardiology
Issue number3
StatePublished - Jan 15 1992

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias'. Together they form a unique fingerprint.

Cite this